Study Summary
This trial is testing if talazoparib works in patients with advanced cancer who have mutations in their DNA repair genes. Talazoparib is a drug that blocks PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die.
- Castration-resistant Prostate Cancer
- Metastatic Cancer
- Metastatic Breast Cancer
- Prostate Cancer
- Stage III Pancreatic Cancer
- Pancreatic Cancer
- Stage III Gastric Cancer
- Breast Cancer
- Stomach Cancer
- Metastatic Pancreatic Endocrine Carcinoma
- Stage IV Gastric Cancer
- Locally Advanced Malignant Solid Tumor
- Postneoadjuvant Therapy Stage IV Gastric Cancer
- Stage III Prostate Cancer
- Stage IV Pancreatic Cancer
- Stage IIIB Breast Cancer
- Stage III Breast Cancer
- Ovarian Cancer
- Stage IVA Gastric Cancer
- Stage IVB Gastric Cancer
- Stage IV Breast Cancer
- HER2-positive Breast Cancer
- Stage IIIB Gastric Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA1 Ovarian Cancer
- Stage III Ovarian Cancer
- Stage IV Prostate Cancer
- Stage IVA Ovarian Cancer
- Postneoadjuvant Therapy Stage III Gastric Cancer
- Stage IIIA Gastric Cancer
- Stage IVB Ovarian Cancer
- Stage IIB Pancreatic Cancer
- Stage IIIA2 Ovarian Cancer
- Stage IIIA Breast Cancer
- Stage IIIA Prostate Cancer
- Stage IVA Prostate Cancer
- Stage IIA Pancreatic Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Prostate Cancer
- Cancer
- Gastric Cancer
- Stage II Pancreatic Cancer
- Stage IVB Prostate Cancer
- Hormone-Refractory Prostate Cancer
- Stage IV Ovarian Cancer
- Platinum-Sensitive Ovarian Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 1 Secondary · Reporting Duration: Up to 30 days after last dose
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Treatment (talazoparib)
1 of 1
Experimental Treatment
36 Total Participants · 1 Treatment Group
Primary Treatment: Biopsy · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is recruitment still taking place for this trial?
"As per clinicaltrials.gov, the recruitment process for this research is currently ongoing. It was initially published on December 29th 2020 and has had its most recent update as of July 27th 2022." - Anonymous Online Contributor
How secure is Biopsy for individuals?
"Due to the limited data available on biopsy's efficacy, our team has assigned it a score of 2 in regards to safety. This is based on its Phase 2 trial status." - Anonymous Online Contributor
How many participants have been included in this clinical research so far?
"According to the specified criteria, 36 people must participate in this investigation. Subjects can join from different hubs such as University of Florida Health Science Center - Gainesville and University of Oklahoma Health Sciences Centre." - Anonymous Online Contributor
Could you elaborate on any additional investigations involving Biopsy?
"In 2010, the City of Hope was at the forefront of biopsy research. Since then, 63 trials have concluded and 58 are still active; a majority of these occuring in Gainesville, Florida." - Anonymous Online Contributor